Genetic Testing

Shifa Health Marks 21 Years of Transformative Mental Health CareShifa Health Marks 21 Years of Transformative Mental Health Care

Shifa Health Marks 21 Years of Transformative Mental Health Care

A Celebration of Innovation, Compassion, and Community EngagementEVERETT, WA / ACCESSWIRE / April 3, 2024 / Shifa Health, a leading…

1 year ago
Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific AgonistRhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist

Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist

-- Three-part study to evaluate safety, tolerability and pharmacokinetics now underway -- -- RM-718 showed potential to reduce body weight…

1 year ago
GENE to develop Worlds Most Advanced Comprehensive Risk Test  Revolutionising Personalised HealthcareGENE to develop Worlds Most Advanced Comprehensive Risk Test  Revolutionising Personalised Healthcare

GENE to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare

MELBOURNE, Australia, March 25, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ:GENE, “Company”, “GENE”), a global leader in guideline-driven genomics-based…

1 year ago
Applied DNA Enters into Agreement with Alphazyme for Scale-Up Manufacturing of its Proprietary Linea(TM) RNAP, Progresses Towards GMP Linea(TM) IVT Production StartApplied DNA Enters into Agreement with Alphazyme for Scale-Up Manufacturing of its Proprietary Linea(TM) RNAP, Progresses Towards GMP Linea(TM) IVT Production Start

Applied DNA Enters into Agreement with Alphazyme for Scale-Up Manufacturing of its Proprietary Linea(TM) RNAP, Progresses Towards GMP Linea(TM) IVT Production Start

- Project To Increase RNAP Manufacturing Capacity and Reduce Unit Costs of Goods -- Project Slated for Completion Coincident with…

1 year ago
Applied DNA to Showcase Linea(TM) DNA and Linea(TM) IVT Platforms at 24th Annual World Vaccine CongressApplied DNA to Showcase Linea(TM) DNA and Linea(TM) IVT Platforms at 24th Annual World Vaccine Congress

Applied DNA to Showcase Linea(TM) DNA and Linea(TM) IVT Platforms at 24th Annual World Vaccine Congress

STONY BROOK, NY / ACCESSWIRE / March 14, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in…

1 year ago
Recce Pharmaceuticals Continues Strategic Partnership with Murdoch Children’s Research InstituteRecce Pharmaceuticals Continues Strategic Partnership with Murdoch Children’s Research Institute

Recce Pharmaceuticals Continues Strategic Partnership with Murdoch Children’s Research Institute

SYDNEY, Australia, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (the Company), the Company developing…

1 year ago
Global Paternity & Relationship Testing Services Market Forecasts 2023-2027 with Executive and Consultant Guides – Changing Values and DTC are Creating New OpportunitiesGlobal Paternity & Relationship Testing Services Market Forecasts 2023-2027 with Executive and Consultant Guides – Changing Values and DTC are Creating New Opportunities

Global Paternity & Relationship Testing Services Market Forecasts 2023-2027 with Executive and Consultant Guides – Changing Values and DTC are Creating New Opportunities

DUBLIN, Feb. 26, 2024 /PRNewswire/ -- The "Paternity & Relationship Testing Services. Global Market Forecasts for Applications and Technologies with…

1 year ago
Applied DNA Announces First Quarter Fiscal Year 2024  Financial ResultsApplied DNA Announces First Quarter Fiscal Year 2024  Financial Results

Applied DNA Announces First Quarter Fiscal Year 2024 Financial Results

- Company On Track to Initiate First-Phase GMP Production Capacity for mRNA Critical Starting Materials During First Half of Calendar…

1 year ago
Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl SyndromeRhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming…

1 year ago
Applied DNA to Report First Quarter Fiscal 2024 Financial Results on Thursday, February 8, 2024Applied DNA to Report First Quarter Fiscal 2024 Financial Results on Thursday, February 8, 2024

Applied DNA to Report First Quarter Fiscal 2024 Financial Results on Thursday, February 8, 2024

STONY BROOK, NY / ACCESSWIRE / February 5, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"),…

1 year ago